Do haemostasis activation markers that predict cardiovascular disease exist?

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 302-308

  Stegnar, Mojca ^a   Vene, Nina ^a   Bozic, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cardiovascular risk; D dimer; Fibrinopeptide A; Haemostasis activation markers; Hypercoagulability; Plasmin antiplasmin complex; Prothrombin fragment 1+2; Soluble fibrin; Thrombin antithrombin complex

Indexed keywords

ANTICOAGULANT AGENT; ANTIPLASMIN; D DIMER; FIBRIN; FIBRINOPEPTIDE A; PLASMIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ARTERY DISEASE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MARKER; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; MEASUREMENT; METHODOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; STROKE; THROMBOSIS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEMOSTASIS; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 14044279161     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083818     Document Type: Conference Paper

References (56)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 1992;326:310-318.
2. Fareed J, Hoppensteadt DA, Leya F, Iqbal O, Wolf H, Bick R. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998;44:1845-1853.
3. Haeberli A. Prothrombin fragment F1+2. In: Jespersen J, Bertina RM, Haverkater F (eds): Laboratory techniques in thrombosis - A manual. Dordrecht-Boston-London, Kluwer, 1999, pp 217-222.
4. Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. J Biol Chem 1980;255:5885-5893.
5. Haeberli A. Fibrinopeptide A (FPA). In: Jespersen J, Bertina RM, Haverkater F (eds): Laboratory techniques in thrombosis - A manual. Dordrecht-Boston-London, Kluwer, 1999, pp 199-207.
6. Wilf J, Minton AP. Soluble fibrin-fibrinogen complexes as intermediates in fibrin gel formation. Biochemistry 1986;25:3124-3133.
7. Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma. Br J Haematol 1995;90:187-194.
8. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90:2236-2240.
9. Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992;67:111-116.
10. Astrup T, Permin TM. Fibrinolysis in the animal organism. Nature 1947; 159: 681-682.
11. van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman PA, Kluft C, Grobbee DE. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemost 2001;85:234-239.
12. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993;342:84-86.
13. Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 2001;21:1701-1705.
14. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995;73:374-379.
15. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001;103:2323-2327.
16. Lowe GD, Rumley A, Sweetnam PM, Yarnell JW, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 2001;86:822-827.
17. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001;21:611-617.
18. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:493-498.
19. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995;91:2520-2527.
20. Biasucci LM, Liuzzo G, Caligiuri G, Quaranta G, Andreotti F, Sperti G, et al. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996;93:2121-2127.
21. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
22. Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998;31:497-505.
23. Ardissino D, Gamba MG, Merlini PA, Rolla A, Barberis P, Demicheli G, Testa S, Bruno N, Specchia G. Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients. Am J Cardiol 1991;68:58B-63B.
24. Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. J Am Coll Cardiol 1991;18:898-903.
25. Wilensky RL, Bourdillon PD, Vix VA, Zeller JA. Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation. J Am Coll Cardiol 993;21:692-699.
26. Ardissino D, Merlini PA, Gamba G, Barberis P, Demicheli G, Testa S, Colombi E, Poli A, Fetiveau R, Montemartini C. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996;93:1634-1639.
27. Li YH, Teng JK, Tsai WC, Tsai LM, Lin LJ, Guo HR, Chen JH. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999;33:1543-1548.
28. Bayes-Genis A, Mateo J, Santalo M, Oliver A, Guindo J, Badimon L, Martinez-Rubio A, Fontcuberta J, Schwartz RS, De Luna AB. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 2000;140:379-384.
29. Figueras J, Monasterio Y, Lidon RM, Nieto E, Soler-Soler J. Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. J Am Coll Cardiol 2000;36:2036-2043.
30. Lee LV, Ewald GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:628-633.
31. Marder VJ, Zareba W, Horan JT, Moss AJ, Kanouse JJ. Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research Investigators. Thromb Haemost 1999;82:1412-1416.
32. Dempfle CE, Kontny F, Abildgaard U. Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost 1999;81:701-704.
33. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase. Thromb Haemost 1996;76:339-343.
34. Hetland O, Knudsen A, Dickstein K, Nilsen DW. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagul Fibrinolysis 2002;13:301-308.
35. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Kamada T, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990;16:377-380.
36. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995;73:527-533.
37. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003;90:1163-1172.
38. Ageno W, Finazzi S, Steidl L, Biotti MG, Mera V, Melzi D'Eril G, Venco A. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002;162:2589-2593.
39. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004;35:1421-1425.
40. Yamazaki M, Uchiyama S, Maruyama S. Alterations of haemostatic markers in various sub-types and phases of stroke. Blood Coagul Fibrinolysis 1993;4:707-712.
41. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992;23:1250-1256.
42. Reganon E, Vila V, Martinez-Sales V, Vaya A, Lago A, Alonso P, Aznar J. Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res 2003;112:217-221.
43. Stott DJ, Spilg E, Campbell AM, Rumley A, Mansoor MA, Lowe GD. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001;12:651-657.
44. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996;27:1296-1300.
45. Di Napoli M, Papa F; Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002;33:1763-1771.
46. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17:3321-335.
47. Côté R, Wolfson C, Solymoss S, Mackey A, Leclerc JR, Simard D, et al. Hemostatic markers in patients at risk of cerebral ischemia. Stroke 2000;31:1856-1862.
48. Herren T, Stricker H, Haeberli A, Do DD, Straub PW. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation 1994;90:2679-2686.
49. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003;107:3191-3198.
50. Jorgensen B, Nielsen JD, Norgard J, Helligso P, Baekgaard N, Egeblad M. Cross-linked fibrin degradation products (XL-FDP) as marker of early rethrombosis in percutaneous transluminal angioplasty. Eur J Vasc Surg 1993;7:720-724.
51. Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 2002;16:1309-1316.
52. Becker RC, Bovill EG, Seghatchian MJ. Samama MM. Pathobiology of thrombin in acute coronary syndromes. Am Heart J 1998;136:S19-31.
53. Tripodi A, Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1+2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost 1994;71:605-608.
54. Greenberg CS, Hursting MJ, Macik BG, Ortel TL, Kane WH, Moore BM. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. Clin Chem 1994;40:1962-1969.
55. Seitz R, Blanke H, Pratorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988;59:541-542.
56. Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983;31:767-778.